For immediate release
Biotectix Introduces a New Conductive Coating Designed for Medical
Devices That Target Cardiac and Nervous System Applications
•
The coating, called Amplicoat™, is a durable electro-conductive coating that is
available for license and commercialization on medical devices through
Biotectix.
•
Amplicoat is designed to maximize efficient and safe function of medical
devices for the heart and nervous system.
•
Amplicoat enables next-generation medical technology by making possible
smaller, less invasive and highly targeted devices.
Ann Arbor, Michigan (Jan. 6, 2015) – Biotectix, a developer of conductive coatings for
medical devices that aim to optimize the communication between devices and physiologic
systems, today introduced a highly durable electro-conductive polymer coating.
The new coating, called Amplicoat™, incorporates Photolink®, a proprietary surface
modification technology developed by Eden Prairie, MN-based SurModics, Inc. (NASDAQ:
SRDX). Designed to enhance communication at the interface between human tissue and a
medical device’s electrode, Amplicoat overcomes the limitations of other conductive
coatings, including poor durability, difficult processing requirements, and limited
performance. The new coating can be easily applied to a variety of metal electrodes,
providing an optimal solution for numerous medical-device applications, including
neurostimulation, cardiac pacing, electrophysiology recordings, cochlear implants, and
gastrointestinal recording and stimulation.
“Amplicoat is a true breakthrough technology that provides a durable electrode coating
that conducts both ionically and electronically, resulting in lower impedance and an
expanded range for safe charge delivery,“ said Dr. Sarah Richardson-Burns, who cofounded Biotectix with Jeff Hendricks, PhD.
Amplicoat enables device electrode miniaturization, offering higher numbers of electrodes
for a given-sized lead or device and providing greater tissue-sensing resolution as well as
more localized stimulation control. The coating enables higher signal fidelity, lower power
requirements, and reduced stimulation thresholds.
“I am very proud of the Biotectix team. The dedication and knowledge needed to
commercialize this technology was significant,” said Omar Amirana, MD, Biotectix Chief
Executive Officer and Senior Vice President of Allied Minds (LSE: ALM), the parent
company of Biotectix.
Biotectix is currently working with customers to incorporate Amplicoat into their medical
devices. In addition, there are non-medical applications for conductive coatings, which are
currently under development at Biotectix.
About Biotectix, LLC.
Biotectix develops electro-conductive coatings technology for medical devices and nonmedical applications. The company, based in Ann Arbor, Michigan, was formed in 2007
through a joint venture between the University of Michigan, Ann Arbor and Allied Minds.
More information can be found on www.biotectix.com.
About Allied Minds
Allied Minds (LSE: ALM) is an innovative U.S. science and technology development and
commercialization company. Operating since 2006, Allied Minds forms, funds, manages
and builds products and businesses based on innovative technologies developed at leading
U.S. universities and federal research institutions. Allied Minds serves as a diversified
holding company that supports its businesses and product development with capital,
central management and shared services. More information about the Boston-based
company can be found at www.alliedminds.com.
Allied Minds Forward-Looking Statement
This press release contains statements that are or may be forward-looking statements,
including statements that relate to the company’s future prospects, developments and
strategies. The forward-looking statements are based on current expectations and are subject
to known and unknown risks and uncertainties that could cause actual results, performance
and achievements to differ materially from current expectations, including, but not limited to,
those risk and uncertainties described in the risk factors included in the company’s regulatory
filings. These forward-looking statements are based on assumptions regarding the present
and future business strategies of the company and the environment in which it will operate in
the future. Each forward-looking statement speaks only as at the date of this press release.
Except as required by law, regulatory requirement, the Listing Rules and the Disclosure and
Transparency Rules, neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new information, future events or
otherwise.
Media Contact:
Christine Dunn
ArcPoint Strategic Communications
617.484.1660, x101
[email protected]
PhotoLink® is a registered trademark of SurModics, Inc.